176 related articles for article (PubMed ID: 37272763)
1. Selective BD2 Inhibitor Exerts Anti-Fibrotic Effects via BRD4/FoxM1/Plk1 Axis in Orbital Fibroblasts From Patients With Thyroid Eye Disease.
Xie Y; Pan Y; Chen Q; Chen Y; Chen G; Wang M; Zeng P; Li Z; Li Z; Wang S; Yang H; Liang D
Invest Ophthalmol Vis Sci; 2023 Jun; 64(7):9. PubMed ID: 37272763
[TBL] [Abstract][Full Text] [Related]
2. TSHR Signaling Stimulates Proliferation Through PI3K/Akt and Induction of miR-146a and miR-155 in Thyroid Eye Disease Orbital Fibroblasts.
Woeller CF; Roztocil E; Hammond C; Feldon SE
Invest Ophthalmol Vis Sci; 2019 Oct; 60(13):4336-4345. PubMed ID: 31622470
[TBL] [Abstract][Full Text] [Related]
3. SOX9 Induces Orbital Fibroblast Activation in Thyroid Eye Disease Via MAPK/ERK1/2 Pathway.
Zhou M; Lin B; Wu P; Ke Y; Huang S; Zhang F; Hei X; Mao Z; Li X; Wan P; Chen T; Yang H; Huang D
Invest Ophthalmol Vis Sci; 2024 Feb; 65(2):25. PubMed ID: 38345552
[TBL] [Abstract][Full Text] [Related]
4. LncRNA LPAL2/miR-1287-5p/EGFR Axis Modulates TED-Derived Orbital Fibroblast Activation Through Cell Adhesion Factors.
Wang N; Hou SY; Qi X; Deng M; Cao JM; Tong BD; Xiong W
J Clin Endocrinol Metab; 2021 Jul; 106(8):e2866-e2886. PubMed ID: 33877318
[TBL] [Abstract][Full Text] [Related]
5. Selective inhibitors of bromodomain BD1 and BD2 of BET proteins modulate radiation-induced profibrotic fibroblast responses.
Liu CS; Rioja I; Bakr A; Veldwijk MR; Sperk E; Herskind C; Weichenhan D; Prinjha RK; Plass C; Schmezer P; Popanda O
Int J Cancer; 2022 Jul; 151(2):275-286. PubMed ID: 35239184
[TBL] [Abstract][Full Text] [Related]
6. The Potential of Artemisinins as Novel Treatment for Thyroid Eye Disease by Inhibiting Adipogenesis in Orbital Fibroblasts.
Guo Y; Cheng Y; Li H; Guan H; Xiao H; Li Y
Invest Ophthalmol Vis Sci; 2023 Jun; 64(7):28. PubMed ID: 37326592
[TBL] [Abstract][Full Text] [Related]
7. The miR-103a-3p/TGFBR3 axis regulates TGF-β-induced orbital fibroblast activation and fibrosis in thyroid-eye disease.
Xie B; Xiong W; Zhang F; Wang N; Luo Y; Chen Y; Cao J; Chen Z; Ma C; Chen H
Mol Cell Endocrinol; 2023 Jan; 559():111780. PubMed ID: 36179941
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic Effect of α-MSH in Primary Cultured Orbital Fibroblasts Obtained from Patients with Thyroid Eye Disease.
Cheng PW; Tsai PJ; Tai MH; Bee YS
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681884
[TBL] [Abstract][Full Text] [Related]
9. Discovery and characterization of bromodomain 2-specific inhibitors of BRDT.
Yu Z; Ku AF; Anglin JL; Sharma R; Ucisik MN; Faver JC; Li F; Nyshadham P; Simmons N; Sharma KL; Nagarajan S; Riehle K; Kaur G; Sankaran B; Storl-Desmond M; Palmer SS; Young DW; Kim C; Matzuk MM
Proc Natl Acad Sci U S A; 2021 Mar; 118(9):. PubMed ID: 33637650
[TBL] [Abstract][Full Text] [Related]
10. Orbital fibroblasts from thyroid eye disease patients differ in proliferative and adipogenic responses depending on disease subtype.
Kuriyan AE; Woeller CF; O'Loughlin CW; Phipps RP; Feldon SE
Invest Ophthalmol Vis Sci; 2013 Nov; 54(12):7370-7. PubMed ID: 24135759
[TBL] [Abstract][Full Text] [Related]
11. A 7-methoxybicoumarin derivative selectively inhibits BRD4 BD2 for anti-melanoma therapy.
Yang GJ; Wang W; Lei PM; Leung CH; Ma DL
Int J Biol Macromol; 2020 Dec; 164():3204-3220. PubMed ID: 32860796
[TBL] [Abstract][Full Text] [Related]
12. Potential role of IGF-1R in the interaction between orbital fibroblasts and B lymphocytes: an implication for B lymphocyte depletion in the active inflammatory phase of thyroid-associated ophthalmopathy.
Wang R; Song D; Zhong Y; Li H
BMC Immunol; 2024 May; 25(1):31. PubMed ID: 38734625
[TBL] [Abstract][Full Text] [Related]
13. Dihydroartemisinin Exerts Antifibrotic and Anti-Inflammatory Effects in Graves' Ophthalmopathy by Targeting Orbital Fibroblasts.
Yang S; Wang X; Xiao W; Xu Z; Ye H; Sha X; Yang H
Front Endocrinol (Lausanne); 2022; 13():891922. PubMed ID: 35663306
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA-130a Is Elevated in Thyroid Eye Disease and Increases Lipid Accumulation in Fibroblasts Through the Suppression of AMPK.
Hammond CL; Roztocil E; Gonzalez MO; Feldon SE; Woeller CF
Invest Ophthalmol Vis Sci; 2021 Jan; 62(1):29. PubMed ID: 33507228
[TBL] [Abstract][Full Text] [Related]
15. [Antifibrotic effect of pirfenidone on orbital fibroblasts in patients with thyroid-associated ophthalmopathy and its mechanisms].
Li DD; Liu Y; Yuan RR; Yu T; Yang B; Pang WY
Zhonghua Nei Ke Za Zhi; 2019 Mar; 58(3):185-190. PubMed ID: 30803176
[No Abstract] [Full Text] [Related]
16. Gypenosides Protect Orbital Fibroblasts in Graves Ophthalmopathy via Anti-Inflammation and Anti-Fibrosis Effects.
Li H; Ma C; Liu W; He J; Li K
Invest Ophthalmol Vis Sci; 2020 May; 61(5):64. PubMed ID: 32462203
[TBL] [Abstract][Full Text] [Related]
17. Disulfiram Exerts Antiadipogenic, Anti-Inflammatory, and Antifibrotic Therapeutic Effects in an
Wang X; Yang S; Ye H; Chen J; Shi L; Feng L; Wang X; Zhang T; Chen R; Xiao W; Yang H
Thyroid; 2022 Mar; 32(3):294-305. PubMed ID: 34605662
[No Abstract] [Full Text] [Related]
18. BET Bromodomain Inhibition as a Therapeutic Strategy in Ovarian Cancer by Downregulating FoxM1.
Zhang Z; Ma P; Jing Y; Yan Y; Cai MC; Zhang M; Zhang S; Peng H; Ji ZL; Di W; Gu Z; Gao WQ; Zhuang G
Theranostics; 2016; 6(2):219-30. PubMed ID: 26877780
[TBL] [Abstract][Full Text] [Related]
19. Affinity map of bromodomain protein 4 (BRD4) interactions with the histone H4 tail and the small molecule inhibitor JQ1.
Jung M; Philpott M; Müller S; Schulze J; Badock V; Eberspächer U; Moosmayer D; Bader B; Schmees N; Fernández-Montalván A; Haendler B
J Biol Chem; 2014 Mar; 289(13):9304-19. PubMed ID: 24497639
[TBL] [Abstract][Full Text] [Related]
20. Breaking boundaries: Pan BETi disrupt 3D chromatin structure, BD2-selective BETi are strictly epigenetic transcriptional regulators.
Tsujikawa LM; Kharenko OA; Stotz SC; Rakai BD; Sarsons CD; Gilham D; Wasiak S; Fu L; Sweeney M; Johansson JO; Wong NCW; Kulikowski E
Biomed Pharmacother; 2022 Aug; 152():113230. PubMed ID: 35687908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
